Apogee reported Phase II maintenance data showing its IL‑13 antibody zumilokibart sustained clinical benefit with dosing every three or six months. The company disclosed durable EASI‑75 responses at one year—including 75% maintenance for three‑month dosing and 85% for six‑month dosing—and a deepening of lesional and itch endpoints across the cohort. Apogee and analysts framed the results as evidence the drug could offer less frequent dosing than current standards, a factor that boosted shares and prompted upgraded peak‑sales forecasts from some analysts. The data require confirmation in larger trials to validate a potential shift in the atopic dermatitis treatment cadence.